ClinConnect ClinConnect Logo
Search / Trial NCT00658788

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

Launched by GALDERMA R&D · Apr 9, 2008

Trial Information

Current as of July 24, 2025

Completed

Keywords

ClinConnect Summary

Same as above.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Diagnosis of moderate to severe plaque psoriasis, defined as 3% - 20% treatable body surface area
  • Overall Disease Severity of at least 3 (moderate)
  • Exclusion Criteria:
  • Surface area involvement too large (\>20% BSA)
  • Psoriasis involving only the scalp, groin, axillae, and/or other intertriginous areas

About Galderma R&D

Galderma R&D is a global leader in dermatological innovation, dedicated to advancing skin health through rigorous research and development. With a strong commitment to scientific excellence, Galderma focuses on creating effective and safe treatments for a variety of skin conditions, including acne, rosacea, and psoriasis. The organization collaborates with healthcare professionals and researchers worldwide to bring cutting-edge solutions to market, ensuring that patients receive the highest quality care. Through its extensive clinical trials and commitment to regulatory compliance, Galderma R&D strives to enhance the understanding of dermatological diseases and improve patient outcomes.

Locations

Norfolk, Virginia, United States

San Diego, California, United States

Newnan, Georgia, United States

Norman, Oklahoma, United States

Snellville, Georgia, United States

Evansville, Indiana, United States

New York, New York, United States

Warren, Ohio, United States

College Station, Texas, United States

Houston, Texas, United States

Seattle, Washington, United States

Madison, Wisconsin, United States

Patients applied

0 patients applied

Trial Officials

Ronald W Gottschalk, MD

Study Director

Galderma R&D

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials